ArticleJournal, genetic engineering & biotechnology2026
Surface-bioengineering of bacteriophage AP205 and MS2 virus-like particles with novel Spytag003 for antigen conjugation.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The insertion of foreign antigens on the coat protein of viruses sometimes interferes with the ability of the coat proteins to assemble into virus-like particles (VLPs). To overcome this limitation, Spytag/Spycatcher bio-conjugation system was developed; however, the conjugation system has pre-existing antibodies that makes it less desirable for vaccine applications. Recently, a novel bio-conjugation system, Spytag003/Spycatcher003, was developed to by-pass this problem. The ability of this new bio-conjugation system to be used to displayed foreign antigens on VLPs has never been explored. Here we assessed whether the insertion of Spytag003 on the coat proteins of AP205 and MS2 would interfere with the ability of the coat proteins to assemble into VLPs. We showed that the insertion of Spytag003 on the N-termini of coat proteins of AP205 and MS2 did not affect their ability to assemble into VLPs. Optimized purification yielded VLPs with high purity, which were successfully conjugated with Spycatcher003 and Ag2/PRA-CSA protein. Mice immunized with the conjugated Spycatcher003 protein elicited high-titer IgG antibodies compared to immunization with unconjugated protein. However, immunization with Ag2/PRA-CSA conjugated or unconjugated to Spytag003-tagged VLPs did not have a significant difference in antibody responses between the two groups. Overall, our results show that the N-termini of AP205 and MS2 are more tolerant to Spytag003 insertions and can be used to conjugate a foreign antigen; as a proof-of-concept, we conjugated a prototype antigen, Ag2/PRA-CSA, on the VLPs. The potential to conjugate diverse antigens on these novel bio-engineered platforms should be explored further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.